“C3R crosslinking only treatment to halt progression of Keratoconus,” says Dr SPS Grewal
C3R Crosslinking, Latest Advancement in Ophthalmology, Internationally Launched This Month
September 28, 2006 (Press Release) --
Chandigarh, September 28, 2006 (InfoMailers.com) --
Grewal Eye Institute (GEI), the premier comprehensive Eye Care Institute based at Chandigarh, has achieved a new high in bringing the latest technological advancement in the field of eye care, by becoming the first and the only institute, not only in India, but in the whole Indian Sub-Continent to offer the revolutionary ‘Corneal Collagen Crosslinking with Riboflavin’ (C3R) Treatment to the masses. The C3R procedure, the only known treatment that has recently been proven to permanently halt the progression of the dreaded Keratoconus disease, was commercially launched globally in the second week of this month itself. By procuring this once-in-a-decade technological break-through in less than two weeks of its launch, GEI is now one of the few eye institutes in the world and the only in Indian subcontinent, to offer comprehensive treatment now available for this previously untreatable disease. This was announced here today by Dr. SPS Grewal, CEO, GEI.
The C3R Treatment is a ray of hope for lacs of Indian Keratoconus Patients, who, before the launch of this advanced procedure, were resigned to the vagaries of fate. This is because Keratoconus is amongst the most dreaded of eye diseases, as in most of the cases, the disease progresses relentlessly during the young age, does not have any acute symptoms initially and thus is often not detected in the early stages. In the advanced stages, the only treatment options available earlier were surgical insertion of ‘Intacs’ or a ‘Corneal Transplant’, both of which have limited success on many grounds, like trauma to the eye, numerous precautions required post-surgery and a long recovery period etc. Most importantly, from both the doctors’ & patients’ perspective, neither of the operations guaranteed a stoppage of the disease. There was always the possibility of setting in of Keratoconus again, even after the operation. This made the situation a frustrating one for both the patient and the doctor.
Speaking at the press conference Dr S.P.S. Grewal, (CEO), GEI said, “C3R is a non-surgical procedure. Also it is the only known procedure that is proven to halt the progression of the dreaded Keratoconus. This treatment now offers an end to a lifetime of waiting and uncertainty for Keratoconus patients. This is a simple one-time treatment that offers a permanent solution to Keratoconus. It does not need heavy precautions or regular follow-up visits, does not need an eye donor as required in ‘Corneal Transplant’, does not require any stitches or incision in the eye, takes just around one hour and the patient recovery is quick.
Source: Infomailers.com
Chandigarh, September 28, 2006 (InfoMailers.com) --
Grewal Eye Institute (GEI), the premier comprehensive Eye Care Institute based at Chandigarh, has achieved a new high in bringing the latest technological advancement in the field of eye care, by becoming the first and the only institute, not only in India, but in the whole Indian Sub-Continent to offer the revolutionary ‘Corneal Collagen Crosslinking with Riboflavin’ (C3R) Treatment to the masses. The C3R procedure, the only known treatment that has recently been proven to permanently halt the progression of the dreaded Keratoconus disease, was commercially launched globally in the second week of this month itself. By procuring this once-in-a-decade technological break-through in less than two weeks of its launch, GEI is now one of the few eye institutes in the world and the only in Indian subcontinent, to offer comprehensive treatment now available for this previously untreatable disease. This was announced here today by Dr. SPS Grewal, CEO, GEI.
The C3R Treatment is a ray of hope for lacs of Indian Keratoconus Patients, who, before the launch of this advanced procedure, were resigned to the vagaries of fate. This is because Keratoconus is amongst the most dreaded of eye diseases, as in most of the cases, the disease progresses relentlessly during the young age, does not have any acute symptoms initially and thus is often not detected in the early stages. In the advanced stages, the only treatment options available earlier were surgical insertion of ‘Intacs’ or a ‘Corneal Transplant’, both of which have limited success on many grounds, like trauma to the eye, numerous precautions required post-surgery and a long recovery period etc. Most importantly, from both the doctors’ & patients’ perspective, neither of the operations guaranteed a stoppage of the disease. There was always the possibility of setting in of Keratoconus again, even after the operation. This made the situation a frustrating one for both the patient and the doctor.
Speaking at the press conference Dr S.P.S. Grewal, (CEO), GEI said, “C3R is a non-surgical procedure. Also it is the only known procedure that is proven to halt the progression of the dreaded Keratoconus. This treatment now offers an end to a lifetime of waiting and uncertainty for Keratoconus patients. This is a simple one-time treatment that offers a permanent solution to Keratoconus. It does not need heavy precautions or regular follow-up visits, does not need an eye donor as required in ‘Corneal Transplant’, does not require any stitches or incision in the eye, takes just around one hour and the patient recovery is quick.
Source: Infomailers.com
Email
Print
SPAM
LEAVE A COMMENT
